Dendreon busts out of biotech with capacity boost

Dendreon say all three of its manufacturing plants should be online and shipping its prostate cancer vaccine by year's end. Provenge is the first vaccine approved for cancer treatment. The manufacturing ramp-up makes Dendreon "a biotech that's become a commercial company now," says Needham & Co. analyst Mark Monane. Sales of the drug were stymied by production constraints. But expansion at a New Jersey plant and  pending regulatory approvals for plants in California and Georgia should eliminate the problem. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.